C-AFHF

FILE C-AFHF·COMPANY·CURATED BY ETERNAL SEARCH

Cognito Therapeutics

gamma stimulation, audiovisual stimulation, neuroprotective therapy

trainingdevice hardware

cognitotx.com·Boston, Massachusetts, United States·$105M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-AFHF

Projects

Spectris AD

phase 3

other · high · Fri Mar 06 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Treat Alzheimer’s disease by slowing cognitive and functional decline and preserving brain volume through gamma-wave stimulation.

Non-invasive visual and auditory stimulation to evoke gamma wave activity in Alzheimer’s patients.

Pivotal-stage Alzheimer’s program with an open-label extension study for participants completing the Hope Study.

Company-reported OVERTURE feasibility results showed slowing of cognitive and functional decline and preservation of brain volume among treated patients.

OLE Hope Study

phase 3

research program · high · Thu Feb 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Extend treatment follow-up for participants who completed the pivotal Hope Study in Alzheimer’s disease.

Open-label extension of a multicenter, randomized, double-blind, sham-controlled adaptive pivotal study; all participants receive Active Sensory Stimulation System GS120 for 60 minutes daily for up to 12 months.

ClinicalTrials.gov record published for the open-label extension study.

Etude Study

undisclosed

research program · high · Thu May 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Assess tolerability, safety, and efficacy of non-invasive sensory stimulation in patients with cognitive impairment.

Multi-center, four-arm prospective dose-adjusting study of sensory stimulation at multiple dose levels.

ClinicalTrials.gov record published for the multi-dose sensory stimulation study.

Overture Study

undisclosed

research program · high · Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Study safety, tolerability, and efficacy of sensory stimulation in people with mild to moderate cognitive impairment.

Randomized, controlled, single-blind multi-center clinical trial using the GammaSense Stimulation system.

Company reports OVERTURE feasibility results showing slowed cognitive and functional decline and preserved brain volume among treated patients.

Reported results include slowing of cognitive and functional decline and preservation of brain volume among treated patients.

Spectris

undisclosed

platform · high

Develop a non-invasive neuroprotective therapy platform designed to evoke specific brain wave activity for Alzheimer’s disease and other neurodegenerative diseases.

Visual and auditory sensory stimulation intended to evoke gamma wave activity.

Company reports development of Spectris as an investigational non-invasive therapy platform, with Spectris AD as the Alzheimer’s disease application.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Projects

Spectris AD

phase 3

other · high · Fri Mar 06 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Treat Alzheimer’s disease by slowing cognitive and functional decline and preserving brain volume through gamma-wave stimulation.

Non-invasive visual and auditory stimulation to evoke gamma wave activity in Alzheimer’s patients.

Pivotal-stage Alzheimer’s program with an open-label extension study for participants completing the Hope Study.

Company-reported OVERTURE feasibility results showed slowing of cognitive and functional decline and preservation of brain volume among treated patients.

OLE Hope Study

phase 3

research program · high · Thu Feb 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Extend treatment follow-up for participants who completed the pivotal Hope Study in Alzheimer’s disease.

ClinicalTrials.gov record published for the open-label extension study.

Etude Study

undisclosed

research program · high · Thu May 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Assess tolerability, safety, and efficacy of non-invasive sensory stimulation in patients with cognitive impairment.

Multi-center, four-arm prospective dose-adjusting study of sensory stimulation at multiple dose levels.

ClinicalTrials.gov record published for the multi-dose sensory stimulation study.

Overture Study

undisclosed

research program · high · Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Study safety, tolerability, and efficacy of sensory stimulation in people with mild to moderate cognitive impairment.

Randomized, controlled, single-blind multi-center clinical trial using the GammaSense Stimulation system.

Company reports OVERTURE feasibility results showing slowed cognitive and functional decline and preserved brain volume among treated patients.

Reported results include slowing of cognitive and functional decline and preservation of brain volume among treated patients.

Spectris

undisclosed

platform · high

Develop a non-invasive neuroprotective therapy platform designed to evoke specific brain wave activity for Alzheimer’s disease and other neurodegenerative diseases.

Visual and auditory sensory stimulation intended to evoke gamma wave activity.

Company reports development of Spectris as an investigational non-invasive therapy platform, with Spectris AD as the Alzheimer’s disease application.